Cytosorbents Cor (CTSO) 4.90 $CTSO
CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb® to Hungary, Czech Republic, Slovakia, and Poland
PR Newswire - Wed Jul 13, 7:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed a formal exclusive distribution agreement with Medial, Ltd., to distribute CytoSorb® in Hungary. In a separate agreement, Meditrade Ltd. will distribute CytoSorb® for all critical care and cardiac surgery applications in the Czech Republic and Slovakia, and for cardiac surgery applications in Poland. Fresenius Medical Care will continue to distribute CytoSorb® in Poland for all critical care applications under the terms of an existing agreement. Both Medial and Meditrade are currently selling CytoSorb® in their respective territories.
CTSO: 4.90 (+0.29)
CytoSorbents and Palex Bring CytoSorb® to Spain and Portugal
PR Newswire - Mon Jun 13, 7:30AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has signed an exclusive distributorship agreement with Palex Medical SA, one of Spain's largest independent medical device distributors, to bring its CytoSorb® therapy to Spain and Portugal. This multi-year agreement includes all critical care applications in these two countries, and is subject to annual minimum purchases of CytoSorb® to maintain exclusivity.
CTSO: 4.90 (+0.29)
CytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia
PR Newswire Europe - Wed Jun 01, 6:01AM CDT
CytoSorbents Corporation , a critical care immunotherapy leader commercializing its flagship CytoSorb((R)) blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that Fresenius Medical Care (FMC), its strategic partner for acute care indications in France, Poland, Sweden, Denmark, Finland, and Norway, has officially initiated its CytoSorb((R)) sales efforts.
CTSO: 4.90 (+0.29)
Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial
PR Newswire - Fri May 27, 7:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that the independent Data Safety Monitoring Board (DSMB) of the current U.S. REFRESH I cardiac surgery trial positively evaluated the safety data from the first 24 patients in a scheduled meeting, found no safety concerns, and recommended continuation of the trial to completion without changes.
CTSO: 4.90 (+0.29)
CytoSorb® Achieves Final Product Registration in Russia
PR Newswire - Wed May 18, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CytoSorb® therapy has achieved final product registration in Russia and will be formally introduced by its distribution partner, INTENSIVMED, to the Russian intensive care and cardiac surgery communities in major near-term conferences.
CTSO: 4.90 (+0.29)
CytoSorbents Continues Strong Growth in Q1 2016
PR Newswire - Mon May 09, 3:10PM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2016.
CTSO: 4.90 (+0.29)
CytoSorbents Establishes Swiss Subsidiary
PR Newswire - Fri May 06, 6:30AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that one of its operating subsidiaries, CytoSorbents Europe GmbH, has established a new wholly-owned subsidiary, CytoSorbents Switzerland GmbH.
CTSO: 4.90 (+0.29)
CytoSorbents to Report Q1 2016 Operating and Financial Results
PR Newswire - Mon May 02, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2016 financial results after the market close on Monday, May 9, 2016.
CTSO: 4.90 (+0.29)
CytoSorbents To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 06, 7:45AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, will present at the 15th Annual Needham Healthcare Conference to be held April 12-13, 2016 in New York City.
CTSO: 4.90 (+0.29)
CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal
PR Newswire - Fri Mar 25, 8:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the company was awarded a $150,000 Phase I Small Business Innovative Research (SBIR) contract for its development program entitled "Mycotoxin Adsorption with Hemocompatible Porous Polymer Beads." A successful Phase I effort will position the company to be competitive for selection in the Phase II SBIR program, valued at more than $1 million.
CTSO: 4.90 (+0.29)
CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting
PR Newswire - Wed Mar 16, 7:41AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, announced the conclusion of its successful 3rd International CytoSorb Users Meeting in Brussels, Belgium. Held one day ahead of the International Symposium of Intensive Care and Emergency Medicine (ISICEM), one of the largest international critical care conferences, the Users Meeting brought together 107 members of the CytoSorb® community from a total of 23 countries, to share data from many new pre-clinical and clinical studies. To date, more than 10,000 CytoSorb® treatments have been performed in thousands of patients.
CTSO: 4.90 (+0.29)
CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium
PR Newswire - Mon Mar 14, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, will host its 3rd International CytoSorb® Users Meeting today in Brussels, Belgium. In addition, CytoSorbents will host a research symposium and exhibit at the 36th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2016), March 15-18, 2016, also in Brussels. ISICEM is among the largest annual conferences for intensive care and emergency medicine, attracting more than 6,200 participants from countries worldwide.
CTSO: 4.90 (+0.29)
CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue
PR Newswire - Wed Mar 09, 3:15PM CST
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world with the goal of preventing or treating organ failure, reports operational and financial results for the fiscal year ending December 31, 2015.
CTSO: 4.90 (+0.29)
CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Thu Feb 04, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference, providing an overview and update on the company.
CTSO: 4.90 (+0.29)
CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
PR Newswire - Mon Feb 01, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA). Funds will be used to help expand manufacturing of CytoSorb® and support sales of CytoSorb® internationally.
CTSO: 4.90 (+0.29)
CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Thu Jan 28, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CEO Dr. Phillip Chan, MD, PhD, will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 in New York City.
CTSO: 4.90 (+0.29)
CytoSorbents elects Volker Humbert, MD as senior manager of Clinical Affairs
M2 - Fri Jan 22, 4:50AM CST
Immunotherapy company CytoSorbents (NasdaqCM:CTSO) announced on Thursday that it has appointed Volker Humbert, MD as senior manager of its Clinical Affairs.
CTSO: 4.90 (+0.29), MDSY: 1.47 (unch)
CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs
PR Newswire - Thu Jan 21, 7:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, today announced that Dr. Volker Humbert, M.D. has joined the company as Senior Manager of Clinical Affairs.
CTSO: 4.90 (+0.29)
CytoSorbents Teams with Medial and Meditrade to Bring CytoSorb® to Hungary, Czech Republic, Slovakia, and Poland
PR Newswire - Wed Jul 13, 7:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, today announced that it has signed a formal exclusive distribution agreement with Medial, Ltd., to distribute CytoSorb® in Hungary. In a separate agreement, Meditrade Ltd. will distribute CytoSorb® for all critical care and cardiac surgery applications in the Czech Republic and Slovakia, and for cardiac surgery applications in Poland. Fresenius Medical Care will continue to distribute CytoSorb® in Poland for all critical care applications under the terms of an existing agreement. Both Medial and Meditrade are currently selling CytoSorb® in their respective territories.
CTSO: 4.90 (+0.29)
CytoSorbents and Palex Bring CytoSorb® to Spain and Portugal
PR Newswire - Mon Jun 13, 7:30AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has signed an exclusive distributorship agreement with Palex Medical SA, one of Spain's largest independent medical device distributors, to bring its CytoSorb® therapy to Spain and Portugal. This multi-year agreement includes all critical care applications in these two countries, and is subject to annual minimum purchases of CytoSorb® to maintain exclusivity.
CTSO: 4.90 (+0.29)
CytoSorbents Announces Fresenius Medical Care Initiates Sales of CytoSorb® in France, Poland and Scandinavia
PR Newswire Europe - Wed Jun 01, 6:01AM CDT
CytoSorbents Corporation , a critical care immunotherapy leader commercializing its flagship CytoSorb((R)) blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that Fresenius Medical Care (FMC), its strategic partner for acute care indications in France, Poland, Sweden, Denmark, Finland, and Norway, has officially initiated its CytoSorb((R)) sales efforts.
CTSO: 4.90 (+0.29)
Independent Data Safety Monitoring Board Recommends Continuation of CytoSorbents REFRESH I Trial
PR Newswire - Fri May 27, 7:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, announced that the independent Data Safety Monitoring Board (DSMB) of the current U.S. REFRESH I cardiac surgery trial positively evaluated the safety data from the first 24 patients in a scheduled meeting, found no safety concerns, and recommended continuation of the trial to completion without changes.
CTSO: 4.90 (+0.29)
CytoSorb® Achieves Final Product Registration in Russia
PR Newswire - Wed May 18, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CytoSorb® therapy has achieved final product registration in Russia and will be formally introduced by its distribution partner, INTENSIVMED, to the Russian intensive care and cardiac surgery communities in major near-term conferences.
CTSO: 4.90 (+0.29)
CytoSorbents Continues Strong Growth in Q1 2016
PR Newswire - Mon May 09, 3:10PM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood purification cartridge to prevent or treat deadly inflammation and organ failure in critically-ill and cardiac surgery patients around the world, reports financial and operational results for the quarter ending March 31, 2016.
CTSO: 4.90 (+0.29)
CytoSorbents Establishes Swiss Subsidiary
PR Newswire - Fri May 06, 6:30AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that one of its operating subsidiaries, CytoSorbents Europe GmbH, has established a new wholly-owned subsidiary, CytoSorbents Switzerland GmbH.
CTSO: 4.90 (+0.29)
CytoSorbents to Report Q1 2016 Operating and Financial Results
PR Newswire - Mon May 02, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q1 2016 financial results after the market close on Monday, May 9, 2016.
CTSO: 4.90 (+0.29)
CytoSorbents To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Wed Apr 06, 7:45AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, will present at the 15th Annual Needham Healthcare Conference to be held April 12-13, 2016 in New York City.
CTSO: 4.90 (+0.29)
CytoSorbents Awarded $150,000 Phase I SBIR Contract for Fungal Mycotoxin Removal
PR Newswire - Fri Mar 25, 8:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the company was awarded a $150,000 Phase I Small Business Innovative Research (SBIR) contract for its development program entitled "Mycotoxin Adsorption with Hemocompatible Porous Polymer Beads." A successful Phase I effort will position the company to be competitive for selection in the Phase II SBIR program, valued at more than $1 million.
CTSO: 4.90 (+0.29)
CytoSorbents Reports on Successful 3rd International CytoSorb® Users Meeting
PR Newswire - Wed Mar 16, 7:41AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, announced the conclusion of its successful 3rd International CytoSorb Users Meeting in Brussels, Belgium. Held one day ahead of the International Symposium of Intensive Care and Emergency Medicine (ISICEM), one of the largest international critical care conferences, the Users Meeting brought together 107 members of the CytoSorb® community from a total of 23 countries, to share data from many new pre-clinical and clinical studies. To date, more than 10,000 CytoSorb® treatments have been performed in thousands of patients.
CTSO: 4.90 (+0.29)
CytoSorbents to Host 3rd International CytoSorb® Users Meeting and ISICEM 2016 Symposium
PR Newswire - Mon Mar 14, 6:00AM CDT
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world, will host its 3rd International CytoSorb® Users Meeting today in Brussels, Belgium. In addition, CytoSorbents will host a research symposium and exhibit at the 36th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2016), March 15-18, 2016, also in Brussels. ISICEM is among the largest annual conferences for intensive care and emergency medicine, attracting more than 6,200 participants from countries worldwide.
CTSO: 4.90 (+0.29)
CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue
PR Newswire - Wed Mar 09, 3:15PM CST
CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® blood filtration technology to reduce deadly uncontrolled inflammation in critically-ill and cardiac surgery patients around the world with the goal of preventing or treating organ failure, reports operational and financial results for the fiscal year ending December 31, 2015.
CTSO: 4.90 (+0.29)
CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
PR Newswire - Thu Feb 04, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference, providing an overview and update on the company.
CTSO: 4.90 (+0.29)
CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program
PR Newswire - Mon Feb 01, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the receipt of $324,606, net of transaction costs, in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority (NJEDA). Funds will be used to help expand manufacturing of CytoSorb® and support sales of CytoSorb® internationally.
CTSO: 4.90 (+0.29)
CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference
PR Newswire - Thu Jan 28, 6:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that its CEO Dr. Phillip Chan, MD, PhD, will present at the 18th Annual BIO CEO & Investor Conference on February 8, 2016 in New York City.
CTSO: 4.90 (+0.29)
CytoSorbents elects Volker Humbert, MD as senior manager of Clinical Affairs
M2 - Fri Jan 22, 4:50AM CST
Immunotherapy company CytoSorbents (NasdaqCM:CTSO) announced on Thursday that it has appointed Volker Humbert, MD as senior manager of its Clinical Affairs.
CTSO: 4.90 (+0.29), MDSY: 1.47 (unch)
CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs
PR Newswire - Thu Jan 21, 7:00AM CST
CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its European Union approved CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients worldwide, today announced that Dr. Volker Humbert, M.D. has joined the company as Senior Manager of Clinical Affairs.
CTSO: 4.90 (+0.29)
